PATENT CLAIM ANALYSIS

Application Number: 16021165
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-11
Patent Classification: ["536", "024500"]

Abstract:
A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5′ terminal side of the region, (c) one or more nucleotide analogs located on 3′ terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.

Claim (Index 1):
A pharmaceutical composition for reducing the level of a transcription product in a cell comprising:\n a double-stranded nucleic acid complex comprising a first nucleic acid strand, a second nucleic acid strand which has a sequence complementary to the first nucleic acid strand, and a hairpin linker which links the first nucleic acid strand and the second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product, and is (a) a nucleic acid strand which comprises at least 4 consecutive DNA nucleotides or modified DNA nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product; and (ii) the second nucleic acid strand is a nucleic acid strand which comprises (a) at least 4 consecutive RNA nucleotides, and (b) one or more modified nucleotides, nucleotide analogs and/or modified nucleotide analogs located 5\u2032 to the at least 4 consecutive RNA nucleotides, and/or (c) one or more modified nucleotides, nucleotide analogs and/or modified nucleotide analogs located 3\u2032 to the at least 4 consecutive RNA nucleotides.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 94.0
- Lexical Diversity: 2.26027
- Patent Class: 536.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15725845', '14303989', '14898630', '14355711', '15977487']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5793773526919594
- 35 USC 102 Novelty (BERT): 0.6723684603773806
- Combined Prediction Score: 0.5886764634605016
- Mean Citation Score: 549.2773380000001
- Max Citation Score: 739.06885
- Similarity Product: 636.6464242014467

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test